Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.53 |
| ▸ | CA1 | P00915 | 10/20 | 0.53 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866357 | 0.88 | CA2 (0.51) | CA2CA1CA9CA12PTGES | |
| SCHEMBL6860565 | 0.85 | CA2 (0.45) | CA2CA1CA9CA12PTGES | |
| SCHEMBL6860195 | 0.78 | TSHR (0.38) | CA9CA12KMT2A | |
| SCHEMBL6866204 | 0.78 | FFAR1 (0.38) | PTGESMEN1KMT2A | |
| SCHEMBL7047775 | 0.76 | PTGES (0.67) | CA2CA1CA9CA12PTGES | |
| SCHEMBL7047776 | 0.76 | CA1 (0.51) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL6866220 | 0.75 | CA2 (0.54) | CA2CA1CA9CA12PTGES | |
| SCHEMBL18132557 | 0.73 | CA1 (0.62) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL2802193 | 0.71 | PTGES (0.83) | CA2CA1CA9CA12PTGES | |
| SCHEMBL6866183 | 0.71 | NPC1 (0.57) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812252-B2 | ACYLSULFONAMIDE DERIVATIVES CONTAINING FLUOROSUBSTITUTEDPHENYLETHYNYL GROUP HAVING A HYPOGLYCEMIC EFFECT AND FREE OF THE SIDE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030191323-A1 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| US-20030181764-A1 | Acylsulfonamide derivatives | AJINOMOTO CO. INC (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1316548-A1 | ACYLSULFONAMIDE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-1300142-A1 | HYPOGLYCEMICS | Ajinomoto Co., Inc. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181764-A1 | Acylsulfonamide derivatives | DPP4, SLC5A2, GLP1R | CA2 1724/4885CA1 3314/4885CA9 2289/4885 |
| US-20030191323-A1 | Hypoglycemic agent | GPR119, IAPP, SLC5A2 | CA2 831/4885CA1 2426/4885CA9 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.